Dashboard
Manage Tickers

VOR Vor Biopharma Inc.

Nasdaq vorbio.com


$ 29.11 $ -1.16 (-3.84 %)    

Thursday, 16-Oct-2025 19:39:27 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 598.23 $ -2.23 (-0.37 %)
DIA $ 458.84 $ -3.15 (-0.68 %)
SPY $ 658.90 $ -4.53 (-0.68 %)
TLT $ 91.49 $ 0.68 (0.75 %)
GLD $ 401.79 $ 9.06 (2.34 %)
$ 29.06
$ 30.68
$ 29.11 x 1
$ 29.97 x 20
$ 28.95 - $ 30.97
$ 2.62 - $ 65.80
418,254
na
184.07M
$ 1.59
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-20-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-20-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-23-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-14-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-25-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

novartis-strengthens-kidney-disease-pipeline-with-promising-data
Novartis Strengthens Kidney Disease Pipeli...
10/16/2025 14:50:29

Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings...

vor-bio-announces-publication-of-results-from-phase-3-study-in-china-evaluating-telitacicept-in-sle-sponsored-by-collaborator-remegen-in-new-england-journal-of-medicine
Vor Bio Announces Publication Of Results F...
10/16/2025 12:04:14

Trial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients respondi...

baird-upgrades-vor-biopharma-to-outperform-raises-price-target-to-64
Baird Upgrades Vor Biopharma to Outperform...
10/15/2025 10:38:23

Baird analyst Jack Allen upgrades Vor Biopharma (NASDAQ:VOR) from Neutral to Outperform and raises the price target from $2...

vor-bios-collaborator-delivers-positive-results-for-telitacicept-in-autoimmune-disorder-that-impacts-tears
Vor Bio's Collaborator Delivers Positive R...
10/14/2025 16:22:03

Telitacicept showed strong efficacy and safety in a 48-week Phase 3 trial for Sjögren's disease, meeting all primary and se...

vor-bio-announces-that-collaborator-remegen-reported-48-week-phase-3-results-from-its-study-in-primary-sjgrens-disease-showing-that-telitacicept-met-all-primary-and-secondary-endpoints-with-high-statistical-significance-at-weeks-24-and-48
Vor Bio Announces That Collaborator Remege...
10/14/2025 12:12:19

Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
10/01/2025 17:06:01

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/30/2025 17:06:34

vor-bio-announces-phase-3-telitacicept-data-in-primary-sjgrens-disease-to-be-presented-at-acr-convergence-2025
Vor Bio Announces Phase 3 Telitacicept Dat...
09/29/2025 11:07:26

verve-capital-reported-99-passive-stake-in-vor-biopharma-as-of-september-18-in-13g-filing
Verve Capital Reported 9.9% Passive Stake ...
09/26/2025 12:26:20

vor-biopharma-files-for-offering-of-up-to-510m-common-shares-by-the-selling-stockholders
Vor Biopharma Files For Offering Of Up To ...
09/24/2025 21:02:11

https://www.sec.gov/Archives/edgar/data/1817229/000119312525215602/d56908ds3.htm

trading-halt-halt-status-updated-at-85500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 8:55:...
09/19/2025 12:55:04

trading-halt-halted-at-75000-pm-et---trading-halt-halt-news-pending
Trading Halt: Halted at 7:50:00 p.m. ET - ...
09/18/2025 23:50:04

Core News & Articles
Reported Earlier, RemeGen Announces Oral P...
09/18/2025 07:11:44

vor-bio-to-present-48-week-phase-3-data-for-telitacicept-in-generalized-myasthenia-gravis-at-aanem-2025-on-october-29-2025
Vor Bio To Present 48-Week Phase 3 Data Fo...
09/17/2025 20:16:33

Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced...

fda-eases-monitoring-burden-for-kidney-disease-patients-on-travere-therapeutics-filspari
FDA Eases Monitoring Burden For Kidney Dis...
08/28/2025 16:40:43

FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FS...

vor-bios-investigational-drug-scores-phase-3-win-in-autoimmune-kidney-disease-trial
Vor Bio's Investigational Drug Scores Phas...
08/27/2025 17:21:08

Vor Bio partner RemeGen reports Phase 3 success for telitacicept in IgA nephropathy, showing a 55% drop in proteinuria and plan...

vor-bio-reports-remegens-telitacicept-meets-primary-endpoint-in-igan-phase-3-trial-remegen-to-submit-bla-for-telitacicept-in-igan
Vor Bio Reports RemeGen's Telitacicept Mee...
08/27/2025 12:03:59

Results reinforce telitacicept's potential across multiple autoimmune diseasesData anticipated to be presented at an upcomi...

hc-wainwright--co-reiterates-buy-on-vor-biopharma-maintains-3-price-target
HC Wainwright & Co. Reiterates Buy on Vor ...
08/14/2025 11:18:47

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Vor Biopharma (NASDAQ:VOR) with a Buy and maintains $3 pri...

vor-bio-rallies-on-strong-data-for-autoimmune-drug-candidate
Vor Bio Rallies On Strong Data For Autoimm...
08/13/2025 15:15:06

Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren...

vor-bio-announces-collaborator-remegen-met-primary-endpoint-in-phase-3-sjgrens-disease-study
Vor Bio Announces Collaborator RemeGen Met...
08/13/2025 12:31:31

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION